Thus, the marker MMP‐2/TIMP‐2 (especially when used in an inclusive model with BNP and TnI) may reduce the rate of misdiagnosis of AL‐CMP and TTR‐CMP and potentially allow for earlier diagnosis/treatment of AL‐CMP. This evidence concerns the gene MMP2 and axial length measurement.